Budesonide orodispersible tablets maintain EoE remission
SAN DIEGO — Patients receiving budesonide orodispersible tablets for the treatment of eosinophilic esophagitis were able to maintain remission through 48 weeks, according to study...
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More